Earnings Releases·Nov 5, 2026, 4:04 PM ET

The Joint Corp. — Third Quarter 2026 Earnings Summary

**Financial Results:** Q3 2026 revenue rose 1% YoY to $13.6 million, while net income from continuing operations surged to $1.5 million from $290,000; however, consolidated net loss was $117,000 versus prior-year income of $855,000, and free cash flow turned negative at $(509,000) compared to $1.5 million previously.
**Guidance Revision:** Full-year 2026 system-wide sales guidance was lowered to $508–$512 million from $519–$552 million, and comp sales guidance for clinics open 13+ months was reduced to (3.5)% to (2.5)% from (3)% to 3%, though consolidated Adjusted EBITDA guidance remains unchanged at $12.5–$13.5 million.
**Strategic Initiatives:** The Company reacquired Regional Developer rights for Texas (141 clinics) for $8.0 million plus potential payments, expects to close underperforming clinics to reduce the total count by approximately 50 in 2026, and anticipates $3.0 million in annualized royalty savings from RD buybacks.
**Capital Return:** The Board authorized an additional $5.0 million stock repurchase program in November 2026, following the repurchase of 461,000 shares for $3.8 million in Q3 and the exhaustion of the prior $12 million authorization.